ASCO GU 2026
ASCO GU 2026
ASCO GU 2026: Induction Ipilimumab + Nivolumab Followed by Consolidating Chemoradiotherapy as Bladder-Sparing Treatment in Stage II/III Urothelial Carcinoma of the Bladder: The Phase 2 Indi-Blade Trial
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Jan-Jaap Mellema discussing results from the phase 2 Indi-Blade trial assessing induction ipilimumab + nivolumab followed by consolidating chemoradiotherapy as bladder-sparing treatment in stage II/III urothelial carcinoma of the bladder.
ASCO GU 2026: Discussant: miR-371a-3p for MRD Detection in Clinical Stage I Testicular Germ Cell Tumors
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a testicular cancer session and a discussant presentation by Dr. Samuel A. Funt, discussing the abstract, “Initial results from CLIMATE, a prospective cohort study assessing the clinical utility of miR-371a-3p as a marker of minimal residual disease in clinical stage 1 testicular germ cell tumor: ANZUP 1906” by Dr. Ben Tran.
ASCO GU 2026: Discussant: Prevention to Progression – Targeting Foundational Biology in RCC
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for advanced renal cell carcinoma (RCC) after anti-PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study” by Dr. Robert Motzer, “Adjuvant pembrolizumab + belzutifan versus pembrolizumab for clear cell RCC: The randomized phase 3 LITESPARK-022 study” by Dr. Toni Choueiri, and “Patient-reported outcomes in resected RCC: Active monitoring vs. durvalumab and tremelimumab in the RAMPART trial” by Dr. Sophie Merrick.
ASCO GU 2026: Emerging Tools in Imaging in Renal Cell Carcinoma
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured an innovations in kidney cancer in 2026 session and a presentation by Dr. Michael Hofman discussing emerging tools in imaging in renal cell carcinoma (RCC). Dr. Hofman started his presentation by emphasizing that theranostics has revolutionized prostate cancer care with PSMA….and the next target is now “clear.”
ASCO GU 2026: Discussant: RETAIN trials and IMvigor011 trial
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Jonathan L. Wright, discussing two abstracts, “ctDNA to guide response-adapted bladder preservation in MIBC: Integrated analysis of the RETAIN trials” by Dr. Pooja Ghatalia and “ctDNA-guided adjuvant atezolizumab in MIBC: Exploratory analysis of ctDNA dynamics in the IMvigor011 trial” by Dr. Thomas Powles. To start his discussion, Dr. Wright emphasized that he will highlight two practical principles for ctDNA:
ASCO GU 2026: Discussant: The Era of ADCs for Urothelial Carcinoma Continues
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart, discussing two abstracts: “Neoadjuvant and adjuvant EV + pembrolizumab for participants with MIBC who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study” by Dr. Matthew Galsky and “RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced urothelial carcinoma” by Dr. Thomas Powles. Dr. Stewart started his discussant presentation by highlighting the KEYNOTE-B15 trial, noting that before this trial, we generally decided if a patient with muscle invasive bladder cancer was a radical cystectomy candidate or better served with bladder preservation. In patients fit for cystectomy, the next decision was whether they were cisplatin eligible or ineligible. If cisplatin eligible, they would be considered for cisplatin-based chemotherapy with immunotherapy or cisplatin based chemotherapy with consideration of adjuvant immunotherapy. If cisplatin ineligible, there may be a consideration for adjuvant immunotherapy based on risk of recurrence or, more recently, based on post-operative ctDNA.
ASCO GU 2026: Imaging for Renal Cell Carcinoma: Current State of the Art
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured an "Innovations in kidney cancer in 2026" session and a presentation by Dr. Shuchi Gulati discussing the current state of the art of imaging for renal cell carcinoma (RCC). There has been a rising incidence of kidney cancer noted between the 1990s-2010, which may reflect increased use and availability of imaging techniques:
ASCO GU 2026: Association of Non-Luminal Subtype with Overall Survival in High Risk NMIBC Patients: Biomarker Results from the Bladder Cancer Prognosis Programme
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Joep de Jong discussing the association of non-luminal subtype with overall survival in high-risk non muscle invasive bladder cancer patients. Non muscle invasive bladder cancer accounts for approximately 75% of all bladder cancer cases, and high-risk non muscle invasive bladder cancer is generally treated by complete TURBT followed by intravesical therapy. While intravesical BCG is considered an effective adjuvant therapy, high-risk non muscle invasive bladder cancer includes a clinically heterogeneous group of cancers with a wide range of recurrence and progression rates. Unfortunately, historical risk stratification models based on clinicopathologic features are relatively inaccurate, and robust prognostic tests are lacking. Furthermore, novel therapeutic regimens have recently been explored, highlighting the need for biomarkers for clinical decision-making.
ASCO GU 2026: Efficacy and Safety of Avelumab + Axitinib Versus Sunitinib in Patients with Very Favorable Risk Advanced RCC: Subgroup Analysis from the JAVELIN Renal 101 Trial
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Balaji Venugopal discussing a subgroup analysis from the JAVELIN Renal 101 trial assessing efficacy and safety of avelumab + axitinib versus sunitinib in patients with very favorable risk advanced RCC. In the JAVELIN Renal 101 phase 3 trial, first-line treatment with avelumab + axitinib in patients with advanced renal cell carcinoma (RCC) significantly prolonged progression-free survival and increased the objective response rate versus sunitinib, irrespective of International Metastatic RCC Database Consortium (IMDC) risk group or number of IMDC risk factors.1
ASCO GU 2026: Circulating KIM-1 in Metastatic RCC with Divergent Histologies: Biomarker Analysis of the CAN-I Trial
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Wenzin Xu discussing biomarker analysis of the CAN-I trial assessing circulating KIM-1 in metastatic renal cell carcinoma (RCC) with divergent histologies. The CAN-I trial was a multi-center single-arm phase II trial that evaluated cabozantinib, nivolumab, and ipilimumab for the treatment of metastatic RCC with divergent histologies.
ASCO GU 2026: Characterization of Depth and Durability of Response in Patients with Previously Untreated Advanced RCC Who Received Cabozantinib + Nivolumab: Long-Term Follow-up and Exploratory Analysis of CheckMate 9ER
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Cristina Suarez discussing long-term follow-up and exploratory analysis of CheckMate 9ER. Cabozantinib + nivolumab is approved as first line treatment in advanced renal cell carcinoma (RCC) based on the CheckMate 9ER trial, which demonstrated superior progression-free survival and overall survival versus sunitinib in this patient population.1
ASCO GU 2026: First Results of a Dose-Escalation Study Evaluating CBM588 with Nivolumab + Ipilimumab in Metastatic RCC
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Miguel Zugman discussing the first results of a dose-escalation study evaluating CBM588 with nivolumab + ipilimumab in metastatic renal cell carcinoma (RCC). CBM588 has shown the potential to improve clinical outcomes when combined with immune checkpoint inhibitors in untreated metastatic RCC.1,2
ASCO GU 2026: Adjuvant Pembrolizumab in Non-Clear Cell RCC After Nephrectomy: An International Multicenter Study
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Razane El Hajj Chehade discussing an international multicenter study assessing adjuvant pembrolizumab in non-clear cell renal cell carcinoma (RCC) after nephrectomy. KEYNOTE-564 demonstrated that adjuvant pembrolizumab improves outcomes after nephrectomy for clear cell RCC.1
ASCO GU 2026: Response of Venous Tumor Thrombi in RCC to Immune Checkpoint Inhibitor Therapy: A Multicenter Retrospective Cohort Study
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Eric Li discussing a multicenter retrospective cohort study assessing the response of venous tumor thrombi in renal cell carcinoma (RCC) to immune checkpoint inhibitor therapy. Approximately 10% of patients with RCC have an associated venous tumor thrombus, the presence of which impacts surgical management and increases perioperative risk.
ASCO GU 2026: Geographic Disparities in the Availability of RCC Clinical Trials in the US
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. George Zhang discussing geographic disparities in the availability of renal cell carcinoma (RCC) clinical trials in the US. Clinical trials for cancer tend to be less available in regions of the US corresponding to high socioeconomic vulnerability,1 however, specific patterns for RCC have yet to be reported. As such, Dr. Zhang and collaborators aimed to evaluate the current county-level distribution of RCC clinical trials in the United States.
ASCO GU 2026: Head to Head Comparison of Pembrolizumab + Axitinib Versus Pembrolizumab + Lenvatinib in Metastatic RCC: Real World Data from the Canadian Kidney Cancer Information System Database
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Alexandre Faco Jr discussing a head-to-head comparison of pembrolizumab + axitinib versus pembrolizumab + lenvatinib in metastatic renal cell carcinoma (RCC). Immune checkpoint inhibitor-tyrosine kinase inhibitor (IO-TKI) combinations have transformed first-line treatment for metastatic RCC. Pembrolizumab + axitinib and pembrolizumab + lenvatinib have each demonstrated efficacy in randomized trials, but there is no head-to-head data comparing these regimens, leaving clinicians with limited real-world evidence to guide individualized treatment decisions.
ASCO GU 2026: Phase 1b/2 KEYMAKER-U03 Substudy 03C of Belzutifan + Zanzalintinib or Belzutifan Monotherapy for Recurrent Clear Cell RCC During or After Anti-PD-(L)1 Therapy
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Robert J. Motzer discussing the phase 1b/2 KEYMAKER-U03 substudy 03C of belzutifan + zanzalintinib or belzutifan monotherapy for recurrent clear cell renal cell carcinoma (RCC) during or after anti-PD-(L)1 therapy. Adjuvant pembrolizumab is a standard of care for patients with RCC at intermediate-high or high risk of recurrence post-surgery.1
ASCO GU 2026: A Randomized Phase 2 Trial of Nivolumab + Relatlimab + Ipilimumab Versus Nivolumab + Ipilimumab in First Line Advanced RCC
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Eric Jonasch discussing a randomized phase 2 trial of nivolumab + relatlimab + ipilimumab versus nivolumab + ipilimumab in first-line advanced renal cell carcinoma (RCC). Ipilimumab + nivolumab is a standard of care for treatment-naïve metastatic clear cell RCC based on the CheckMate-214 trial.1
ASCO GU 2026: The Phase II IVORY Trial: Ivonescimab in Metastatic Clear Cell RCC After Immune Checkpoint Inhibitor Therapy
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Nazli Dizman discussing the phase II IVORY trial assessing ivonescimab in metastatic clear cell renal cell carcinoma (RCC) after immune checkpoint inhibitor therapy. Immune checkpoint inhibitor-based combinations, such as dual immune checkpoint inhibitors or immune checkpoint inhibitor plus a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI), constitute the first-line treatment for metastatic clear cell RCC.
ASCO GU 2026: REJOICE-PanTumor01: A Phase 2 Signal-Seeking Study of Raludotatug Deruxtecan in Patients with Advanced or Metastatic Gynecologic or Genitourinary Tumors
- Details
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking study of raludotatug deruxtecan in patients with advanced or metastatic gynecologic or genitourinary tumors.